Acadia jumps on pimavanserin deal

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) rose $1.34 (134%) to $2.34 on 2.9 million shares on Monday after granting Biovail Corp. (TSX:BVF; NYSE:BVF) exclusive rights in the U.S. and Canada to develop...